Trial Profile

A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Matched Healthy Control Participants.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Opnurasib (Primary)
Indications Carcinoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Novartis Pharmaceuticals

07 Oct 2024 Status changed from recruiting to discontinued.
02 Aug 2024 Planned End Date changed from 16 Jul 2024 to 30 Aug 2024.
02 Aug 2024 Planned primary completion date changed from 16 Jul 2024 to 30 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com